Skip to main navigation Skip to search Skip to main content

Biomarkers in lung cancer treatment

  • Rekha Thiruvengadam
  • , Carmelin Durai Singh
  • , Benod Kumar Kondapavuluri
  • , Srisugamathi Gurusamy
  • , Baskar Venkidasamy
  • , Muthu Thiruvengadam
  • Saveetha Institute of Medical and Technical Sciences (Deemed to be University)
  • Dr. D. Y. Patil Vidyapeeth, Pune
  • Sri Shakthi Institute of Engineering and Technology

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Lung carcinoma (LC) is the primary cause of millions of deaths worldwide. As LC is typically diagnosed at a later stage, its prevention and treatment are difficult. The pathological basis of both types of LC, namely non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is highly determined. The only treatments available for LC are surgical resection and chemotherapy, which require sophisticated new treatments. Biomarkers are promising treatment options, because they can be used for both diagnosis and treatment. Typical signaling molecules known as biomarkers identify abnormalities in cellular activity and serve as prognostic and diagnostic indicators. Biomarkers show great promise in clinical decision making, early and quick diagnosis, recurrence of illness, and tracking the effectiveness of cancer treatments. This review provides an overview of biomarkers, their benefits, and future directions for those new to the field of biomarker research in LC therapy.

Original languageEnglish
Article number120267
JournalClinica Chimica Acta
Volume572
DOIs
StatePublished - 15 May 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Biomarkers
  • Diagnosis
  • Lung carcinoma
  • Pathogenesis
  • Therapy

Fingerprint

Dive into the research topics of 'Biomarkers in lung cancer treatment'. Together they form a unique fingerprint.

Cite this